These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 36614823)

  • 1. Patient Selection for Pemafibrate Therapy to Prevent Adverse Cardiovascular Events.
    Izumida T; Imamura T; Narang N; Kinugawa K
    J Clin Med; 2022 Dec; 12(1):. PubMed ID: 36614823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between Pemafibrate Therapy and Triglyceride to HDL-Cholesterol Ratio.
    Imamura T; Narang N; Kinugawa K
    J Clin Med; 2022 May; 11(10):. PubMed ID: 35628945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Pemafibrate Therapy on Reducing Small Dense Low-Density-Lipoprotein-Cholesterol Levels in Patients with Hypertriglyceridemia.
    Hida Y; Imamura T; Kinugawa K
    J Clin Med; 2023 Nov; 12(21):. PubMed ID: 37959379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Half Dose Once-Daily Pemafibrate Effectively Improved Hypertriglyceridemia in Real Practice.
    Iitake C; Iitake K
    J Clin Med Res; 2019 Oct; 11(10):690-695. PubMed ID: 31636783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Marked effects of novel selective peroxisome proliferator-activated receptor α modulator, pemafibrate in severe hypertriglyceridemia: preliminary report.
    Iitake C; Masuda D; Koseki M; Yamashita S
    Cardiovasc Diabetol; 2020 Nov; 19(1):201. PubMed ID: 33246467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of pemafibrate on glucose metabolism markers and liver function tests in patients with hypertriglyceridemia: a pooled analysis of six phase 2 and phase 3 randomized double-blind placebo-controlled clinical trials.
    Yokote K; Yamashita S; Arai H; Araki E; Matsushita M; Nojima T; Suganami H; Ishibashi S
    Cardiovasc Diabetol; 2021 May; 20(1):96. PubMed ID: 33947390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Pemafibrate in Patients with Stroke and Hypertriglyceridemia: Baseline Cerebral Artery Diseases and 3-Month Laboratory Outcomes.
    Hoshino T; Ishizuka K; Toi S; Seki M; Kitagawa K
    J Atheroscler Thromb; 2022 Jul; 29(7):1020-1030. PubMed ID: 34248089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world Profile of a Selective Peroxisome Proliferator-activated Receptor α Modulator (SPPARMα) in Japanese Patients with Renal Impairment and Dyslipidemia.
    Komatsu T; Miura T; Joko K; Sunohara D; Mochidome T; Kasai T; Ikeda U
    Intern Med; 2021 Sep; 60(17):2741-2748. PubMed ID: 33776008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of a novel selective peroxisome proliferator-activated receptor-α modulator, pemafibrate, on hepatic and peripheral glucose uptake in patients with hypertriglyceridemia and insulin resistance.
    Matsuba I; Matsuba R; Ishibashi S; Yamashita S; Arai H; Yokote K; Suganami H; Araki E
    J Diabetes Investig; 2018 Nov; 9(6):1323-1332. PubMed ID: 29603684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα): Pooled Analysis of Phase 2 and 3 Studies in Dyslipidemic Patients with or without Statin Combination.
    Yamashita S; Arai H; Yokote K; Araki E; Matsushita M; Nojima T; Suganami H; Ishibashi S
    Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31698825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study.
    Pradhan AD; Paynter NP; Everett BM; Glynn RJ; Amarenco P; Elam M; Ginsberg H; Hiatt WR; Ishibashi S; Koenig W; Nordestgaard BG; Fruchart JC; Libby P; Ridker PM
    Am Heart J; 2018 Dec; 206():80-93. PubMed ID: 30342298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial.
    Ishibashi S; Arai H; Yokote K; Araki E; Suganami H; Yamashita S;
    J Clin Lipidol; 2018; 12(1):173-184. PubMed ID: 29203092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Pemafibrate, a Novel Selective PPARα Modulator, on Lipid and Glucose Metabolism in Patients With Type 2 Diabetes and Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial.
    Araki E; Yamashita S; Arai H; Yokote K; Satoh J; Inoguchi T; Nakamura J; Maegawa H; Yoshioka N; Tanizawa Y; Watada H; Suganami H; Ishibashi S
    Diabetes Care; 2018 Mar; 41(3):538-546. PubMed ID: 29298800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and methods of an open-label, randomized controlled trial to evaluate the effect of pemafibrate on proteinuria in CKD patients (PROFIT-CKD).
    Seki M; Nakano T; Tanaka S; Matsukuma Y; Funakoshi K; Ohkuma T; Kitazono T
    Clin Exp Nephrol; 2023 Apr; 27(4):358-364. PubMed ID: 36738362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of pemafibrate, a novel selective peroxisome proliferator-activated receptor-alpha modulator (SPPARMα), on urinary protein excretion in IgA nephropathy with hypertriglyceridemia.
    Tanaka A; Nakamura T; Sato E; Chihara A; Node K
    CEN Case Rep; 2020 May; 9(2):141-146. PubMed ID: 31950425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Low-Dose Pemafibrate Therapy for Hypertriglyceridemia in Patients with Type 2 Diabetes.
    Bando H; Taneda S; Manda N
    JMA J; 2021 Apr; 4(2):135-140. PubMed ID: 33997447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Applications of a Novel Selective PPARα Modulator, Pemafibrate, in Dyslipidemia and Metabolic Diseases.
    Yamashita S; Masuda D; Matsuzawa Y
    J Atheroscler Thromb; 2019 May; 26(5):389-402. PubMed ID: 30930344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of K-877 (Pemafibrate), a Selective PPARα Modulator, in European Patients on Statin Therapy.
    Ginsberg HN; Hounslow NJ; Senko Y; Suganami H; Bogdanski P; Ceska R; Kalina A; Libis RA; Supryadkina TV; Hovingh GK
    Diabetes Care; 2022 Apr; 45(4):898-908. PubMed ID: 35238894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Pemafibrate on Hemorheology in Patients with Hypertriglyceridemia and Aggravated Blood Fluidity Associated with Type 2 Diabetes or Metabolic Syndrome.
    Iwakura T; Yasu T; Tomoe T; Ueno A; Sugiyama T; Otani N; Kawamoto S; Nakajima H
    J Clin Med; 2023 Feb; 12(4):. PubMed ID: 36836015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Case report: a potential modulation of coronary atheroma by lowering triglyceride-rich lipoproteins with pemafibrate: insights from serial near-infrared spectroscopy imaging.
    Murata Y; Kataoka Y; Asaumi Y; Noguchi T
    Cardiovasc Diagn Ther; 2023 Feb; 13(1):100-108. PubMed ID: 36864976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.